CMRX Earnings

CMRX reported its FY2024Q2 earnings on 2024-08-13, showcasing a revenue of 129.00K against an estimate of 260.00K, resulting in a -50.38% surprise. The EPS was -0.23, surpassing the expected -0.23 by 0% . The stock experienced a -6.1% price change on the earnings day and a 28.05% change over the next five days, reflecting market reactions to the results.

Following CMRX's FY2024Q2 earnings announcement on 2024-08-13, the stock price moved by -6.10% on the day of the release. Over the subsequent five days, it saw a 28.05% change. Historically, CMRX's stock price tends to shift by an average of +17.85% in the 10 days leading up to earnings and +3.05% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate CMRX’s annual revenue to reach 630.50K, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CMRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CMRX's stock price typically moves by +17.85% in the 10 days before its earnings and +3.05% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of undefined and revenue of 630.50K.

The earnings call reveals mixed signals. Financial performance shows slight improvements with reduced net loss and decreased G&A expenses, but increased R&D expenses and ongoing net loss pose financial risks. The cash runway until 2026 is positive, but regulatory and operational risks remain. The Q&A highlights management's preparation for NDA submissions and commercialization efforts, but analysts' sentiment is cautious due to unclear responses on certain risks. Overall, the sentiment is neutral as positive and negative factors balance each other out.